Vimarsana
Biggest News Aggregation in the World

Page 3 - Glucose Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Glucose Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Glucose Test Today - Breaking & Trending Today

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients - Vimarsana News

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...

Lexicon Strengthens Management Team With Two New Executives - Vimarsana News

Lexicon Strengthens Management Team With Two New Executives

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 -- Lexicon...

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting - Lexicon Pharmaceuticals (NASDAQ:LXRX) - Vimarsana News

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting - Lexicon Pharmaceuticals (NASDAQ:LXRX)

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care &

Can deep brain stimulation unlock the cure for severe depression? - Vimarsana News

Can deep brain stimulation unlock the cure for severe depression?

A multidisciplinary team of clinicians, engineers, and neuroscientists has identified a unique biomarker in the brain that indicates recovery from treatment-resistant depression, utilizing deep brain stimulation (DBS) and artificial intelligence. The discovery, which allows for real-time monitoring and tailoring of treatment, could revolutionize the approach to managing severe forms of depression.

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 - Vimarsana News

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

THE WOODLANDS, Texas, Aug. 21, 2023 -- Lexicon Pharmaceuticals, Inc. today announced that analyses of clinical study results relating to INPEFA™ , its recently approved drug for heart...